Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
Jul 27,2023
Fudan University, School of Management "Science and Technology Entrepreneur Camp" entered Medicilon: "Hardcore Technology" as the background color, Adding "luster" to new drug research and development
On July 14, Professor Xiongwen Lu, Dean of the School of Management of Fudan University, led the professor group of Fudan School of Management and the students of the fifth phase of the Fudan Science and Technology Entrepreneur Camp into the Zhangjiang Park of Shanghai Medicilon Inc. (Medicilon) to conduct a site visit.
More
Fudan University, School of Management "Science and Technology Entrepreneur Camp" entered Medicilon: "Hardcore Technology" as the background color, Adding "luster" to new drug research and development
Jul 14,2023
Another honor! Medicilon won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023
The press conference released the most influential list of China's pharmaceutical industry in 2022-2023. Medicilon once again won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023 based on its comprehensive strength.
More
Another honor! Medicilon won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023
Jul 12,2023
Medicilon topped the "Top 10 Most Influential CRO Enterprises" in the 2023 China Biopharmaceutical Industry Value List
The 9th BIO-PHARM2023 and the 2023 China Biopharmaceutical Industry Value List Awards Ceremony were grandly opened in Suzhou. Medicilon was listed in the "Top 10 Most Influential CRO Enterprises".
More
Medicilon topped the "Top 10 Most Influential CRO Enterprises" in the 2023 China Biopharmaceutical Industry Value List
Jul 12,2023
Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs
Recently, Shanghai Medicilon Inc. (Medicilon) and EyeCure reached a strategic collaboration. The two parties will carry out comprehensive collaboration in the field of ophthalmic cell and gene therapy.
More
Medicilon and EyeCure reached a strategic collaboration to facilitate the preclinical research and development of ophthalmic cell and gene drugs
Jul 12,2023
Five times in a row! Medicilon was shortlisted in the "2022 China CXO Enterprises Top 20 List"
On June 27, the 2022 China Pharmaceutical Industry Top 100 Series List was released. Shanghai Medicilon Inc. was once again shortlisted in the "China CXO Enterprises Top 20 List".
More
Five times in a row!  Medicilon was shortlisted in the "2022 China CXO Enterprises Top 20 List"
Jul 12,2023
CRO joins with technical companies to promote the transformation of innovative drug research and development, Medicilon and SciMatchmaker reached a strategic collaboration
Recently, Shanghai Medicilon Inc. (Medicilon) and SciMatchmaker reached a strategic collaboration. The two parties have reached an agreement on collaboration in new drug research and development and resource sharing.
More
CRO joins with technical companies to promote the transformation of innovative drug research and development, Medicilon and SciMatchmaker reached a strategic collaboration
Jul 07,2023
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division
Medicilon, a one-stop pharmaceutical preclinical R&D service platform CRO, recognizes the importance of drug discovery as the cornerstone of new drug innovation. Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division.
More
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division
Jul 04,2023
Medicilon appeared at the 25th SAPA-NE Annual Conference
The 25th annual conference of SAPA-NE (Sino-American Pharmaceutical Professionals Association–New England/Boston) was successfully held in Boston, MA. During the conference, the Medicilon team conducted in-depth exchanges with a lot of pharmaceutical colleagues, and discussed about the industry situation and market prospects.
More
Medicilon appeared at the 25th SAPA-NE Annual Conference
Jun 26,2023
Reelected for 4 consecutive years! Medicilon is on the list of "Top 20 Chinese R&D CRO Enterprises in 2023"
On June 16, 2023, the "2023 Chinese Pharmaceutical CRO Enterprise Ranking" was released. Shanghai Medicilon Inc. was once again shortlisted for the 2023 China Pharmaceutical CRO Enterprise Ranking List.
More
Reelected for 4 consecutive years!  Medicilon is on the list of "Top 20 Chinese R&D CRO Enterprises in 2023"
Jun 26,2023
Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I
MindRank's GLP-1RA small molecule oral drug has been successfully administered to the first subject in clinical phase I. Medicilon as a strategic partner of MindRank, provided MDR-001 with API process development and preparation R&D services to help speed up its research and development.
More
Medicilon congratulates MindRank's GLP-1RA small molecule oral drug for successfully administering the first subject in clinical phase I
Jun 21,2023
Medicilon Assists Toll Biotech's TollB-001 tablets, a new class 1.1 drug, to officially approve for clinical trials by the FDA
Recently, the IND application of TollB-001 Tablets, a class 1.1 new drug for rheumatoid arthritis by Toll Biotech, has been officially approved by the FDA. Medicilon provided pharmaceutical research services, including raw materials and preparation, for TollB-001 tablets, which accelerated the research process.
More
Medicilon Assists Toll Biotech's TollB-001 tablets, a new class 1.1 drug, to officially approve for clinical trials by the FDA
Jun 21,2023
To build an integrated AI platform for early drug discovery and evaluation, Medicilon and DP Technology reached a strategic collaboration
Recently, Shanghai Medicilon Inc. (Medicilon) and DP Technology Ltd. announced the signing of a strategic collaboration agreement. The two parties will work together to build an integrated AI platform for early drug discovery and evaluation based on AI4S.
More
To build an integrated AI platform for early drug discovery and evaluation, Medicilon and DP Technology reached a strategic collaboration